The Hidden Risk in Your Research Supply Chain
In the current economic climate, as research budgets continue to tighten, companies are increasingly focused on ensuring that investment in primary market research delivers real business impact. However, this pressure to maximise ROI shouldn’t come at the expense of data integrity and robustness. In fact, when budgets are constrained and projects become higher stakes, the quality of your underlying data becomes even more critical.
However, commissioners of primary research operate under the assumption that those participating are:
- Who they claim to be
- Human – particularly as AI and automated response tools have made it easier to fabricate authentic-looking survey participation.
Whether you’re developing a bioreactor, chromatography equipment, diagnostic instrument or a medical device, your go-to-market strategy is reliant on understanding the needs of “real” customers. But if your sample includes even a small percentage of fraudulent or misrepresented participants, your insights are flawed and so are any business decisions you make as a result.
The Scale of the Problem
In primary market research targeting specialist audiences, such as scientists, process development/manufacturing staff or Lab Managers, fraudulent participants are an increasingly documented concern. Industry estimates suggest that approximately 5% of research spend is lost to fraud (BHBIA white paper).
Research across the wider sector also reveals recurring patterns:
- Researchers consistently report encountering fraudulent respondents in studies that combine online recruitment and incentives
- Large-scale surveys have seen thousands of responses systematically excluded due to duplication, metadata inconsistencies, and unverifiable credentials
- Even within qualitative research, imposters have been documented misrepresenting themselves as professionals, emphasising that professional status alone does not guarantee authenticity
Why the Life Sciences/Medtech sectors are particularly vulnerable?
The conditions that attract either low-quality respondents or bots are especially prominent within highly specialised fields such as Life Sciences & MedTech sectors as follows:
- Relatively high incentives – Quality respondents in niche fields command premium incentives. This attracts opportunists willing to fabricate credentials in return for a good payout
- Credential gatekeeping – When studies require specific expertise (e.g. bioprocess engineering, regulatory affairs, clinical operations), fewer people qualify. Panel providers face pressure to fill quotas, sometimes with more “questionable” candidates
- Low verification friction – Most panel providers rely on self-reported credentials from screeners. Without independent validation, a generic respondent can claim specialised expertise and move forward
- Infrequent audits – Unlike clinical research where source documentation is mandatory, commercial primary research rarely undergoes post-hoc validation of respondent claims
All the above commonly results in a biased pool of respondents skewed toward whoever is most motivated to complete surveys in return for financial reward; not necessarily who has genuine expertise and would be the best fit for that specific study.
What Does This Mean for Your Strategy?
If you’re making important decisions based on unvalidated respondents, you’re operating with invisible risk:
- Misaligned product roadmaps: You’re optimising for problems that don’t actually exist, or missing critical ones that do
- Wasted messaging investment: Your value propositions don’t resonate because you’ve built them on false assumptions about customer priorities
- Competitive vulnerability: Competitors using better-validated research may be closer to actual market needs
5 Key Questions to Ask Your Primary Market Research Partners
When evaluating a primary market research partner, data quality and respondent verification should be non-negotiable. Do not see it as a hygiene factor – it should be a deal breaker.
Here are five questions that will help you assess whether an agency is taking validation seriously:
- How do you independently verify professional credentials beyond self-reported screening answers?
- Do you cross-reference claimed employment against LinkedIn profiles or external professional databases?
- What’s your process for detecting credential inflation or fabrication in screener responses?
- If a respondent’s credentials prove inaccurate following completion, what action(s) do you take?
- Are you willing to share examples of respondents you rejected during validation and why?
In Conclusion
If your research partners struggle to provide clear answers to any of these questions, data quality and respondent validation is likely not a priority for them.
When evaluating a research partner, just ask yourself: “Would I trust this data if our board asked us to justify every respondent’s credentials?”
If you hesitate when answering this question, then your agency hasn’t done their job.
Within the Life Sciences & Medtech sectors, your competitive advantage rests on understanding your market with precision. That precision starts with knowing who’s actually responding to the questions that you need answering.
To find out more regarding our unique approach to data quality and respondent validation within the Life Sciences & MedTech sectors, please get in touch.
Andy Way, Mar 26